COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer.
作者： Sharon A Glynn , Robyn L Prueitt , Lisa A Ridnour , Brenda J Boersma , Tiffany M Dorsey
关键词:
摘要: Background Inducible cyclooxgenase-2 (COX-2) is commonly overexpressed in breast tumors and a target for cancer therapy. Here, we studied the association of COX-2 with survival how this influenced by tumor estrogen HER2 receptor status Akt pathway activation.
biomedcentral.com
springer.com
doaj.org参考文章(38)
Kotha Subbaramaiah, Kotha Subbaramaiah, Howard T. Thaler, Baoheng Du, Louise R. Howe, Anthony M. C. Brown, Jaime L. Masferrer, Clifford Hudis, William J. Muller, Andrew J. Dannenberg, Jay Patel, Aparna Deora, Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Research. ,vol. 62, pp. 5405- 5407 ,(2002)
Karin Gwyn, Elizabeth Half, Kyle Wathen, Aysegul A Sahin, Xi Ming Tang, Frank A. Sinicrope, Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ Cancer Research. ,vol. 62, pp. 1676- 1681 ,(2002)
Jill E Kucab, Cathy Lee, Ching-Shih Chen, Jiuxiang Zhu, C Blake Gilks, Maggie Cheang, David Huntsman, Erika Yorida, Joanne Emerman, Michael Pollak, Sandra E Dunn, Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Research. ,vol. 7, pp. 1- 12 ,(2005) , 10.1186/BCR1294
Florian Heitz, Philipp Harter, Hans-Joachim Lueck, Annette Fissler-Eckhoff, Fatemeh Lorenz-Salehi, Stefanie Scheil-Bertram, Alexander Traut, Andreas du Bois, Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases European Journal of Cancer. ,vol. 45, pp. 2792- 2798 ,(2009) , 10.1016/J.EJCA.2009.06.027
Poonamally Bapsy, Henry Gomez, Digumarti Raghunadharao, Robert Paridaens, Stephen Jones, Silvia Falcon, Marina Carpentieri, Antonello Abbattista, Jean-Pierre Lobelle, Luc Yves Dirix, Jorge Ignacio, Shona Nag, Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib Journal of Clinical Oncology. ,vol. 26, pp. 1253- 1259 ,(2008) , 10.1200/JCO.2007.13.3744
Birgitte Vrou Offersen, Jan Alsner, Karen Ege Olsen, Rikke Riisbro, Nils Brünner, Flemming Brandt Sørensen, Boe Sandahl Sørensen, Birgitte Olrik Schlemmer, Jens Overgaard, , A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncologica. ,vol. 47, pp. 618- 632 ,(2008) , 10.1080/02841860801958295
David G Hicks, Sarah M Short, Nichole L Prescott, Shannon M Tarr, Kara A Coleman, Brian J Yoder, Joseph P Crowe, Toni K Choueiri, Andrea E Dawson, G Thomas Budd, Raymond R Tubbs, Graham Casey, Robert J Weil, None, Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. The American Journal of Surgical Pathology. ,vol. 30, pp. 1097- 1104 ,(2006) , 10.1097/01.PAS.0000213306.05811.B9
C J Witton, S J K Hawe, T G Cooke, J M S Bartlett, Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology. ,vol. 45, pp. 47- 54 ,(2004) , 10.1111/J.1365-2559.2004.01898.X
Yasunori Emi, Kaoru Kitamura, Yasunori Shikada, Yoshihiro Kakeji, Ikuo Takahashi, Shinichi Tsutsui, Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. Surgery. ,vol. 131, pp. 217- 221 ,(2002) , 10.1067/MSY.2002.119580
K. Park, S. Han, E. Shin, H.-J. Kim, J.-Y. Kim, Cox-2 expression on tissue microarray of breast cancer Ejso. ,vol. 32, pp. 1093- 1096 ,(2006) , 10.1016/J.EJSO.2006.05.010